Skip to content

Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults With Type 2 Diabetes: A Cohort Study.

Oct 2026 · Diabetes Care · 0 citations
Medicine

Abstract

Objective

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated cardiorenal benefits in individuals with type 2 diabetes, but safety data in older adults remain limited. We evaluated the real-world safety of SGLT2is compared with dipeptidyl peptidase 4 inhibitors (DPP-4is) among individuals aged ≥75 years with type 2 diabetes. RESEARCH

Design

AND

Methods

We conducted a population-based, active-comparator, new-user cohort study using administrative health databases from British Columbia, Canada. We included individuals aged ≥75 years with type 2 diabetes initiating SGLT2is or DPP-4is between 1 January 2021 and 31 December 2023. Primary outcomes were infection, diabetic ketoacidosis, acute kidney injury, fall, fracture, and all-cause hospitalization. Cox regression with propensity score-based standardized mortality ratio weighting was used to estimate hazard ratios (HRs).

Results

The study included 4,997 SGLT2i initiators (median age, 79 years; 37% women) and 1,289 DPP-4i initiators (median age, 82 years; 50% women). Compared with DPP-4i initiation, SGLT2i initiation was associated with lower risks of acute kidney injury (HR 0.76, 95% CI 0.60-0.95) and all-cause hospitalization (HR 0.87, 95% CI 0.77-0.98), with no difference in risk of infection. No differences were observed in risk of diabetic ketoacidosis, falls, or fractures, although CIs were compatible with both benefit and harm.

Conclusions

In individuals aged ≥75 years with type 2 diabetes, SGLT2i initiation was not associated with increased risk of harm compared with DPP-4i initiation, although estimates were imprecise for some outcomes. These findings may support consideration of SGLT2is as a treatment option in this population.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.